<![CDATA[Chosa Oncolygy +78% idag?]]>Fandt dette på LinkedIn:

Tillykke til Allarity Therapeutics med FDA's Fast Track-betegnelse til stenoparib til fremskreden kræft i æggestokkene.

Denne anerkendelse fremhæver både det presserende uopfyldte medicinske behov inden for æggestokkræft og potentialet i lægemiddelspecifik DRP® til at forbedre patientresultaterne.

Hos CHOSA Oncology er vi især glade for at se denne milepæl, da Stenoparib DRP® er drevet af den samme underliggende teknologi, som også understøtter vores egen Platin-DRP®. Dette validerer yderligere styrken af DRP-platformen® til at vejlede præcisionsonkologi og demonstrerer, hvordan præcisionsmedicinsk diagnostik kan fremskynde regulatoriske veje og understøtte hurtigere adgang til nye behandlinger.

Vi lykønsker Allarity Therapeutics -teamet med at fremme patientcentreret innovation og ser frem til den fortsatte indvirkning af DRP-teknologi® til at forbedre resultaterne for kræftpatienter over hele verden.

Kender Proinvestorfolket noget til Chosa eller Allarity???

]]>https://dev.proinvestor.com/forum/topic/447589/chosa-oncolygy-78-idagRSS for NodeFri, 12 Jun 2026 11:47:19 GMTWed, 03 Sep 2025 16:52:30 GMT60<![CDATA[Reply to Chosa Oncolygy +78% idag? on Wed, 03 Sep 2025 16:54:34 GMT]]>
Link Preview Image
Allarity Therapeutics | LinkedIn

Allarity Therapeutics | 2,678 followers on LinkedIn. PERSONALIZED CANCER CARE. REALIZED. | Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersholm, Denmark.

favicon

(www.linkedin.com)

]]>https://dev.proinvestor.com/forum/post/9494394https://dev.proinvestor.com/forum/post/9494394Wed, 03 Sep 2025 16:54:34 GMT<![CDATA[Reply to Chosa Oncolygy +78% idag? on Wed, 03 Sep 2025 16:53:34 GMT]]>
Link Preview Image
🎉 Congratulations to Allarity Therapeutics on the FDA Fast Track designation to stenoparib for advanced ovarian cancer. This recognition highlights both the urgent unmet medical need in ovarian… | CHOSA Oncology

🎉 Congratulations to Allarity Therapeutics on the FDA Fast Track designation to stenoparib for advanced ovarian cancer. This recognition highlights both the urgent unmet medical need in ovarian cancer and the potential of drug-specific DRP® to improve patient outcomes. At CHOSA Oncology, we are especially excited to see this milestone, as the Stenoparib DRP® is powered by the same underlying technology that also underpins our own Platin-DRP®. This further validates the strength of the DRP® platform in guiding precision oncology and demonstrates how precision medicine diagnostics can accelerate regulatory pathways and support faster access to new therapies. We congratulate the Allarity Therapeutics team on advancing patient-centered innovation and look forward to the continued impact of DRP® technology in improving outcomes for cancer patients worldwide. 👉 Learn more about our Platin-DRP®:  https://lnkd.in/dR_Q2cdg

favicon

LinkedIn (www.linkedin.com)

]]>https://dev.proinvestor.com/forum/post/9494405https://dev.proinvestor.com/forum/post/9494405Wed, 03 Sep 2025 16:53:34 GMT